Ani Pharmaceuticals (ANIP) Liabilities from Discontinued Operations (2012 - 2013)
Ani Pharmaceuticals' (ANIP) quarterly Liabilities from Discontinued Operations came in at $131613.0 in Q3 2013, down 64.08% quarter-over-quarter from $366390.0 in Q2 2013.
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Liabilities from Discontinued Operations (2012 - 2013) Analysis & Trends
Ani Pharmaceuticals has disclosed Liabilities from Discontinued Operations across 2 years of filings, most recently posting $131613.0 for Q3 2013.
- In Q3 2013, Liabilities from Discontinued Operations changed N/A year-over-year to $131613.0; the TTM figure through Sep 2013 stood at $131613.0 (changed N/A YoY), while the FY2012 annual figure was $370766.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at $131613.0 for Q3 2013 at Ani Pharmaceuticals, down from $366390.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of $370766.0 in Q4 2012 to a low of $131613.0 in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.55 Bn | 38.89 Bn | 2.15 Bn |
| 2 | Viatris | 19.15 Bn | 18.26 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.87 Bn | 9.70 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.32 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 401.76 Mn | 360.51 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2013 | 131,613.00 |
| Jun 30, 2013 | 366,390.00 |
| Dec 31, 2012 | 370,766.00 |